Latest On Opiant Pharmaceuticals, Inc (OPNT):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-02-11 06:12 EST | News | What's The Opiant CVR Worth? | N/A |  |
| 2023-01-26 23:40 EST | News | Horizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals (update) | N/A | |
| 2023-01-20 08:58 EST | News | Opiant wins FDA priority review for opioid overdose therapy | N/A | |
| 2023-01-14 01:31 EST | News | Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In | N/A | |
| 2022-11-14 13:17 EST | News | Opiant Pharmaceuticals GAAP EPS of -$1.93 misses by $0.42, revenue of $0.2M misses by $3.48M | N/A | |
About Opiant Pharmaceuticals, Inc (OPNT):
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
General
- Name Opiant Pharmaceuticals, Inc
- Symbol OPNT
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 30
- Last Split Factor1:100
- Last Split Date2014-12-31
- Fiscal Year EndJuly
- IPO Date2016-01-04
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.opiant.com
Valuation
- Trailing PE 4.43
- Forward PE 26.74
- Price/Sales (Trailing 12 Mt.) 1.74
- Price/Book (Most Recent Quarter) 1.46
- Enterprise Value Revenue 0.76
- Enterprise Value EBITDA 0.33
Financials
- Most Recent Quarter 2020-10-31
- Profit Margin -6%
- Operating Margin -8%
- Return on Assets -3%
- Return on Equity -5%
- Revenue 29.63 million
- Earnings Per Share $1.79
- Revenue Per Share $6.97
- Gross Profit 14.19 million
- Quarterly Earnings Growth 29.4%
Highlights
- Market Capitalization 47.04 million
- EBITDA 9.49 million
- Analyst Target Price $41.33
- Book Value Per Share $8.34
Share Statistics
- Shares Outstanding 4.29 million
- Shares Float 3.87 million
- % Held by Insiders 567%
- % Held by Institutions 31.07%
- Shares Short 10798
- Shares Short Prior Month 10123
- Short Ratio 0.18
Technicals
- Beta 0.8
- 52 Week High $14.98
- 52 Week Low $6.79
- 50 Day Moving Average 12.64
- 200 Day Moving Average 9.29
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Opiant Pharmaceuticals, Inc (OPNT) Dividend Calendar:
Opiant Pharmaceuticals, Inc (OPNT) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Opiant Pharmaceuticals, Inc (OPNT) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Opiant Pharmaceuticals, Inc (OPNT) Chart:
Opiant Pharmaceuticals, Inc (OPNT) News:
Below you will find a list of latest news for Opiant Pharmaceuticals, Inc (OPNT) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Opiant Pharmaceuticals, Inc (OPNT) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest OPNT Trades:
Opiant Pharmaceuticals, Inc (OPNT) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-29 | 8-K (Current report) | |
| 2020-09-08 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-08-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-28 | 8-K (Current report) | |
| 2020-07-13 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-06-16 | 8-K (Current report) | |
| 2020-06-16 | 8-K (Current report) | |
| 2020-06-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-11 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-08 | 8-K (Current report) | |
| 2020-06-03 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-05-26 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-21 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
Opiant Pharmaceuticals, Inc (OPNT) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Opiant Pharmaceuticals, Inc (OPNT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 567%
Institutional Ownership: 3107%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-04 | Thomas T. Thomas | Director | Buy | 500.00 | 8.05 | 4,025.00 | 5,000.00 | |
| 2020-09-03 | Thomas T. Thomas | Director | Buy | 2,500.00 | 8.40 | 21,000.00 | 4,500.00 | |
| 2020-06-15 | Ann L. MacDougall | Director | Buy | 2,000.00 | 12,000.00 | | ||
| 2020-06-15 | Craig A Collard | Director | Buy | 2,000.00 | 2,000.00 | | ||
| 2020-06-15 | Thomas T. Thomas | Director | Buy | 2,000.00 | 2,000.00 | | ||
| 2020-06-15 | Richard J Daly | Director | Buy | 2,000.00 | 3,800.00 | | ||
| 2020-06-15 | Gabrielle Alison Silver | Director | Buy | 2,000.00 | 6,515.00 | | ||
| 2020-06-15 | Sinclair Michael | Director | Buy | 2,000.00 | 71,220.00 | | ||
| 2020-06-11 | David D O'Toole | Chief Financial Officer | Buy | 1,000.00 | 8.74 | 8,740.00 | 15,365.00 | |
| 2020-06-10 | Gabrielle Alison Silver | Director | Buy | 2,730.00 | 9.13 | 24,924.90 | 4,515.00 | |
| 2020-05-26 | David D O'Toole | Chief Financial Officer | Buy | 1,000.00 | 11.00 | 11,000.00 | 14,365.00 | |
| 2020-01-08 | Phil Skolnick | Chief Scientific Officer | Sell | 2,842.00 | 13.46 | 38,253.32 | 7,193.00 | |
| 2020-01-07 | Phil Skolnick | Chief Scientific Officer | Buy | 4,150.00 | 10,035.00 | | ||
| 2020-01-07 | David D O'Toole | Chief Financial Officer | Buy | 4,150.00 | 13,365.00 | | ||
| 2020-01-07 | ROGER CRYSTAL | Chief Executive Officer | Buy | 13,650.00 | 22,125.00 | | ||
| 2020-01-07 | Phil Skolnick | Chief Scientific Officer | Sell | 3,043.00 | 13.36 | 40,654.48 | 4,150.00 | |
| 2020-01-07 | Phil Skolnick | Chief Scientific Officer | Sell | 2,900.00 | 13.60 | 39,440.00 | 5,885.00 | |
| 2020-01-07 | Mark Jason Heath Ellison | Insider | Buy | 4,150.00 | 9,680.00 | | ||
| 2020-01-06 | Phil Skolnick | Chief Scientific Officer | Sell | 515.00 | 13.80 | 7,107.00 | 8,785.00 | |
| 2020-01-02 | Phil Skolnick | Chief Scientific Officer | Buy | 10,000.00 | 9.00 | 90,000.00 | 10,000.00 | |